Markus Möbs

Markus Möbs

Auto-generated profile, based on publicly available information

Markus Möbs

Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Institute of Pathology Berlin 10117

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2019 in Leukemia
Verified
Journal Article
Open access
PDF file
OGon behalf of the EuroClonality-NGS Working Group
on behalf of the EuroClonality-NGS Working Group
BSBlanca Scheijen
Blanca Scheijen
RMRuud W. J. Meijers
Ruud W. J. Meijers
JRJos Rijntjes
Jos Rijntjes
MKMichèle Y. van der Klift
Michèle Y. van der Klift
PGPatricia J. T. A. Groenen
Patricia J. T. A. Groenen
One of the hallmarks of B lymphoid malignancies is a B cell clone characterized by a unique footprint of clonal immunoglobulin (IG) gene rearrangements that serves as a diagnostic marker for clonality assessment. The EuroClonality/BIOMED-2 assay is currently the gold standard for analyzing IG heavy chain (IGH) and κ light chain (IGK) gene rearrangements of suspected B cell lymphomas. Here, the EuroClonality-NGS Working Group presents a multicentre technical feasibility study of a novel approach involving next-generation sequencing (NGS) of IGH and IGK loci rearrangements that is highly suitable for detecting IG gene rearrangements in frozen and formalin-fixed paraffin-embedded tissue specimens. By employing gene-specific primers for IGH and IGK amplifying smaller amplicon sizes in combination with deep sequencing technology, this NGS-based IG clonality analysis showed robust performance, even in DNA samples of suboptimal DNA integrity, and a high clinical sensitivity for the detection of clonal rearrangements. Bioinformatics analyses of the high-throughput sequencing data with ARResT/Interrogate, a platform developed within the EuroClonality-NGS Working Group, allowed accurate identification of clonotypes in both polyclonal cell populations and monoclonal lymphoproliferative disorders. This multicentre feasibility study is an important step towards implementation of NGS-based clonality assessment in clinical practice, which will eventually improve lymphoma diagnostics.

25 January 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
SMSoulafa Mamlouk
Soulafa Mamlouk
LCLiam Harold Childs
Liam Harold Childs
DADaniela Aust
Daniela Aust
DHDaniel Heim
Daniel Heim
FMFriederike Melching
Friederike Melching
CSChristine Sers
Christine Sers
Genetic heterogeneity between and within tumours is a major factor determining cancer progression and therapy response. Here we examined DNA sequence and DNA copy-number heterogeneity in colorectal cancer (CRC) by targeted high-depth sequencing of 100 most frequently altered genes. In 97 samples, with primary tumours and matched metastases from 27 patients, we observe inter-tumour concordance for coding mutations; in contrast, gene copy numbers are highly discordant between primary tumours and metastases as validated by fluorescent in situ hybridization. To further investigate intra-tumour heterogeneity, we dissected a single tumour into 68 spatially defined samples and sequenced them separately. We identify evenly distributed coding mutations in APC and TP53 in all tumour areas, yet highly variable gene copy numbers in numerous genes. 3D morpho-molecular reconstruction reveals two clusters with divergent copy number aberrations along the proximal–distal axis indicating that DNA copy number variations are a major source of tumour heterogeneity in CRC.

11 August 2016 in Blood
Verified
Journal Article
Open access
PDF file
JNJan P. Nicolay
Jan P. Nicolay
KMKarin Müller-Decker
Karin Müller-Decker
ASAnne Schroeder
Anne Schroeder
MBMarkus Brechmann
Markus Brechmann
MMMarkus Möbs
Markus Möbs
KGKarsten Gülow
Karsten Gülow
Key Points: DMF induces specific cell death in CTCL cells and inhibits CTCL tumor growth and metastasis in vivo via inhibition of NF-κB. DMF therefore represents a promising, nontoxic novel therapeutic approach to treating CTCL.

21 April 2009 in European Journal of Haematology
Verified
Journal Article
Closed access
PDF file
UHUlrike Heider
Ulrike Heider
JRJessica Rademacher
Jessica Rademacher
BLBritta Lamottke
Britta Lamottke
MMMaren Mieth
Maren Mieth
MMMarkus Moebs
Markus Moebs
OSOrhan Sezer
Orhan Sezer

7 September 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
SDSilvia Darb-Esfahani
Silvia Darb-Esfahani
CDCarsten Denkert
Carsten Denkert
ASAlbrecht Stenzinger
Albrecht Stenzinger
CSChristoph Salat
Christoph Salat
BSBruno Sinn
Bruno Sinn
SLSibylle Loibl
Sibylle Loibl
Background: TP53 mutations are frequent in breast cancer, however their clinical relevance in terms of response to chemotherapy is controversial.

1 March 2018 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
DBDaniel Benten
Daniel Benten
YBYasmin Behrang
Yasmin Behrang
LULudmilla Unrau
Ludmilla Unrau
VWVictoria Weissmann
Victoria Weissmann
Gerrit Wolters-EisfeldGerrit Wolters-Eisfeld
Gerrit Wolters-Eisfeld
JSJoerg Schrader
Joerg Schrader
Clinical options for systemic therapy of neuroendocrine tumors (NET) are limited. Development of new drugs requires suitable representative in vitro and in vivo model systems. So far, the unavailability of a human model with a well-differentiated phenotype and typical growth characteristics has impaired preclinical research in NET. Herein, we establish and characterize a lymph node–derived cell line (NT-3) from a male patient with well-differentiated pancreatic NET. Neuroendocrine differentiation and tumor biology was compared with existing NET cell lines BON and QGP-1. In vivo growth was assessed in a xenograft mouse model. The neuroendocrine identity of NT-3 was verified by expression of multiple NET-specific markers, which were highly expressed in NT-3 compared with BON and QGP-1. In addition, NT-3 expressed and secreted insulin. Until now, this well-differentiated phenotype is stable since 58 passages. The proliferative labeling index, measured by Ki-67, of 14.6% ± 1.0% in NT-3 is akin to the original tumor (15%–20%), and was lower than in BON (80.6% ± 3.3%) and QGP-1 (82.6% ± 1.0%). NT-3 highly expressed somatostatin receptors (SSTRs: 1, 2, 3, and 5). Upon subcutaneous transplantation of NT-3 cells, recipient mice developed tumors with an efficient tumor take rate (94%) and growth rate (139% ± 13%) by 4 weeks. Importantly, morphology and neuroendocrine marker expression of xenograft tumors resembled the original human tumor. Implications: High expression of somatostatin receptors and a well-differentiated phenotype as well as a slow growth rate qualify the new cell line as a relevant model to study neuroendocrine tumor biology and to develop new tumor treatments. Mol Cancer Res; 16(3); 496–507. ©2018 AACR.